You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In his look back at the past decade, BuzzFeed News' Peter Aldhous writes that direct-to-consumer genetic testing has led to "Facebook for genes."
The genomics-focused fertility management company claims that 23andMe failed to meet its contractual obligations within a research collaboration.
23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.
Researchers analyzed data from 23andMe and the UK Biobank to find that errors of recombination, like uniparental disomy, can be present among healthy individuals.
23andMe had sued Ancestry.com for, among other things, infringing a patent related to a method for determining the degree to which two people in a database are related.
Direct-to-consumer genetic testing company 23andMe is partnering with clinical trial firm TrialSpark to address low recruitment into clinical trials.
The companies will offer customers a way to mine 23andMe's customer base for subjects with specific genetic or clinical features, and design and conduct a trial around them.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
23andMe and GlaxoSmithKline's partnership has uncovered half a dozen drug targets but also raised ethical questions, the Wall Street Journal reports.
US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.
A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.
Nature News writes that viral genomic surveillance in the US faces systemic issues.
President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.
In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.